Lee Rachel M, Maithel Shishir K
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, 1365B Clifton Road, 4th Floor, Atlanta, GA 30322, USA.
Division of Surgical Oncology, Department of Surgery, Emory Liver and Pancreas Center, Winship Cancer Institute, Emory University School of Medicine, 1365B Clifton Road, 4th Floor, Atlanta, GA 30322, USA.
Surg Oncol Clin N Am. 2019 Oct;28(4):631-643. doi: 10.1016/j.soc.2019.06.014.
Distal cholangiocarcinoma is a rare malignancy with a dismal prognosis. Because of its location and aggressive nature, patients often present with locally advanced or metastatic disease, and effective treatment options are limited. For patients with resectable disease, surgery is the only chance for cure, but achieving an R0 resection is paramount. Optimal adjuvant therapy in resectable disease remains under investigation. Randomized controlled trials investigating neoadjuvant therapy and its impact on resectability and long-term outcomes are needed to continue to improve the outcomes of patients with distal cholangiocarcinoma.
远端胆管癌是一种预后不佳的罕见恶性肿瘤。由于其位置和侵袭性,患者常表现为局部晚期或转移性疾病,有效的治疗选择有限。对于可切除疾病的患者,手术是唯一的治愈机会,但实现R0切除至关重要。可切除疾病的最佳辅助治疗仍在研究中。需要进行随机对照试验来研究新辅助治疗及其对可切除性和长期预后的影响,以持续改善远端胆管癌患者的预后。